Introduction
Important progress has been made in the last 10 years in the development and the clinical use of drugs for treating HIV-1 infection. To date, nearly 25 antiretroviral drugs belonging to six drug classes have been licensed for the treatment of HIV-1. Most of them target the viral enzymes reverse transcriptase and protease, others the gp41, CCR5/gp120, and very recently the integrase. The combined use of all these drugs and the increased clinical experience have substantially improved the clinical management of HIV-1 infection in terms of delaying disease progression, prolonging survival, and improving quality of life [1] . Nevertheless, antiretroviral therapy can still fail to be fully suppressive and new viral variants emerge, thus allowing HIV-1 to become resistant to one or more drugs by accumulating mutations either alone or in multiple and complex patterns [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
Integrase inhibitors and CCR5 antagonists represent the two more recent classes developed to block HIV replication. Understanding the mechanisms underlying resistance development to both existing and novel drugs is thus essential for a better clinical management of resistant viruses and for preventing further resistance development and spread.
Resistance to integrase inhibitors
HIV-1 integrase represents a new and important target of potential clinical relevance [13] [14] [15] ; and two INIs, raltegravir and elvitegravir, have shown promising results in clinical trials. The first of these two inhibitors has been recently made available for clinical practice [16,17 , 18-20] .
The HIV-1 integrase enzyme is responsible for the chromosomal integration of the newly synthesized double-stranded viral DNA into the host genomic DNA [21, 22] , enabling HIV-1 to establish a permanent genetic reservoir that can both initiate new virus production and replicate through cellular mitosis. HIV-1 integrase is a 32-kDa protein of 288 amino acids comprising three functional domains: the N-terminal domain (NTD; amino acids 1-49), the catalytic core domain (CCD; amino acids , and the C-terminal domain (CTD; amino acids 213-288) [23] . The NTD contains a highly conserved zinc-binding H 12 H 16 C 40 C 43 motif [22, 24] involved in the stabilization folding and proper multimerization of the integrase subunits [25] [26] [27] . The CCD, which plays a critical role in integrase enzymatic activity, contains the catalytic D 64 D 116 E 152 motif, which is conserved in all retroviral integrases [22, 24, [28] [29] [30] [31] [32] . Several important residues in integrase are in contact with the human lens epithelium-derived growth factor (LEDGF/p75), which is an essential cellular cofactor for HIV integration, linking the integrase to chromatin [33] [34] [35] [36] [37] .
The CTD has strong but nonspecific DNA-binding activity and is involved in the binding with viral and cellular DNA [38] [39] [40] [41] . This domain, required for the integration reaction, is involved also in protein oligomerization and interactions with the reverse transcriptase [39] .
Following reverse transcription, a multimeric form of integrase enzyme catalyzes two reactions: the first is a cleavage of two conserved nucleotides from the 3 0 ends of both LTR strands of the viral cDNA (3 0 processing) [42] . This reaction takes place within a nucleoprotein complex, referred to as the pre-integration complex (PIC), in the cytoplasm [43] . The PIC is transported through the nuclear pore to the nucleus where the second step (strand transfer) occurs. This consists of the insertion and the covalent ligation of the viral cDNA into the host genome [42, 44, 45] .
As there is no human homologue of this enzyme, the HIV integrase represents a rational and important target for treating HIV infection and preventing AIDS. All integration steps can potentially be inhibited and each step can be considered a possible drug target [13] [14] [15] .
To date, the strand transfer inhibitors (STIs) have been the most successful class of INIs, with the development of two clinically relevant inhibitors (elvitegravir and raltegravir) [16,17 ,18-20] .
As it is the case with other antiviral drugs, drug resistance to INIs occurs both in vitro and in vivo through the selection of mutations within HIV genome. So far, 64 integrase mutations (S17T, M50T, H51Y, T66AIK, L68IV, L74AIM, I72V, E92QG, Q95K, T97A, L101I, K111T, T112I, H114Y, S119GR, F121Y, T125K, A128T, E138AK, G140ACS, Y143CHR, Q146KP, S147G, Q148HKR, V151I, S153AY . For instance, N155H and Q148R/H/K have been identified as 'signature' resistance mutations in patients failing both raltegravir and elvitegravir, whereas Y143R/C was mainly associated with raltegravir, and E92Q and S147G were mainly associated with elvitegravir. Other resistance integrase mutations were observed in patients failing raltegravir and/or elvitegravir (L74M, T97A, E138K, G140SAC, and G163R). However, they had little or no effect on drug susceptibility in vitro in the absence of a primary 'signature' mutation, thus suggesting rather a secondary role for viral fitness rescue and/or increasing resistance [6,17 ,18,49,52-61] .
The relevance of all integrase mutations in clinical practice is yet to be defined in light of the lack of long-term follow-up of treated patients, the limited data about the prevalence of INI-associated mutations in INI-naïve patients [either untreated or treated with antiretrovirals (ARVs) not containing INI], and the scattered information about conservation and variability of HIV integrase in clean datasets. One report of two patients who had previously experienced virological failure on elvitegravir and were then switched to raltegravir suggested that these two drugs have clinically significant crossresistance, as the antiviral response after the switch was not significant [62] . Some studies have recently started to analyze, within the public Los Alamos database, the prevalence of natural polymorphisms and mutations associated with INI resistance in the HIV-1 integrase, either in clade B [50] or from different subtypes of group M, N, and O viruses [63] [64] [65] . In addition, a single study added some information regarding the integrase variability in drug-naïve patients vs. ARV-treated patients with non-INI drugs (i.e., reverse transcriptase inhibitors and protease inhibitors) [66] .
In addition to its obvious clinical relevance, the identification and characterization of conserved regions/residues within the HIV-1 integrase is of fundamental importance, which can help in designing new therapeutic strategies aimed at driving the virus to mutate at key amino acids that are crucial for the maintenance of sufficient viral fitness [50, [63] [64] [65] [66] .
currently discovered ([6,12, [63] [64] [65] ). This situation is true for all primary signature mutations (Y143HCR, S147G, Q148HKR, and N155H) or secondary mutations (H51Y, T66AK, L74A, E92Q, E138K, G140SAC, K160N, R166S, E170A, S230R, and R263K) found in patients failing raltegravir-containing or elvitegravir-containing regimens. Other resistance mutations (Q95K, F121Y, Q146P, and S153Y) known to reduce HIV-1 susceptibility in vitro to elvitegravir are also completely absent. Differently, some secondary mutations recently found in patients failing raltegravir-containing and/or elvitegravir-containing regimens [17 , 18] such as T66I, L68IV, E138A, E157Q, G163KR, and D232N mutations are rare (frequency <1%), whereas L74IM, T97A, S119GR, V151I, and I203M are present as natural polymorphisms with frequency of 1.3-6%; T206S and S230N are remarkably frequent (>10%).
The primary mutation T112I associated with resistance in vitro to the MK-2048, a potent second-generation INI able to inhibit some HIV-1-resistant variants generated with first-generation compounds [53] , occurs at a low frequency. Six additional mutations associated with in-vitro resistance to INIs different than raltegravir or elvitegravir showed more than 10% variability (I72V, T125AV, M154I, V165I, and V201I).
All these data consistently show that all primary mutations associated with resistance to INIs clinically relevant today are absent or highly infrequent in INInaïve patients.
However, for some secondary INI resistance-associated mutations, differences in prevalence between the distinct studies were observed. For instance, four integrase mutations (I84V, M154IL, and V165I, which are not associated with resistance to raltegravir or elvitegravir) showed a significant increase in the prevalence in HIV-1 B ART-treated patients compared with ART-naïve ones [66] . Two of them, previously associated with in-vitro resistance to other INIs (strand-transfer inhibitors as well as DNA-binding inhibitors and 3 0 processing inhibitors) [50] , M154I and V165I, occurred at 6% frequency in untreated patients, reaching 21.3 and 13.4%, respectively, in ART-treated patients. M154L was absent in ARTnaïve patients and reached 5.7% in ART-treated ones. Similarly, I84V mutation occurred at 1.5% frequency in untreated patients, reaching at 5.7% frequency in ARTtreated patients [66] . All these mutations within the Los Alamos Database, which mostly came from ART-naïve patients, had a frequency similar to that observed in HIV-1B subtype ART-naïve patients [50, 65] .
The mechanisms of this observed difference on the prevalence of some integrase mutations between drug-naïve and ART-treated patient populations need further investigations. It is conceivable that specific drug-pressure induced by protease inhibitors or in particular reverse transcriptase inhibitors (RTIs) may select or induce mutations also in different target regions within the same gene. For instance, very recent observations by us and by other groups indicate that there are some associations between integrase and reverse transcriptase resistance mutations in ART-failing patients [66] [67] [68] , supporting the hypothesis of a close physical interaction between the viral integrase and reverse transcriptase and a potential co-evolution of some of their mutations. Further studies are required to elucidate this point of potentially relevant implications in clinical practice.
So far, in patients failing raltegravir-containing regimens, two main different pathways of raltegravir resistance have been generally associated with virological failure, each involving one signature primary mutation at positions N155 or Q148, plus some secondary mutations (L74M, E92Q, E138K, G140SAC, and G163R) important for viral fitness rescue and/or increasing resistance It is possible that pre-existing integrase mutations, both occurring as natural polymorphisms and/or acquired/ selected by previous virological failures with antiviral regimens different from INIs, may influence the integrase genetic pathways to develop resistance and could reduce the 'genetic barrier' and thus accelerate treatment failure to INIs.
In this context, HIV-1 group and subtype differences may also have an impact on evolution of resistance to INIs, as it has been described for protease inhibitors, NRTI, and NNRTIs [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] . Hackett et al., by analyzing 1304 sequences from group M, N, and O viruses, have recently reported that some of the mutations associated with resistance to raltegravir and/or elvitegravir, such as L74M, L74I, T97A, and E157Q, as well as others INIresistance mutations (V165I, V201I, and T206S) occurred as natural polymorphisms (1%) and differently according to different HIV-1 subtype/CRF/group [62] . The significance of these polymorphic residues to the current generation of INIs is not yet known.
Interestingly, in this context, recent studies also showed promising results of efficacy of INIs in HIV-2. Despite a 40% heterogeneity between the HIV-1 and HIV-2 integrase genes, phenotypic susceptibility to raltegravir and elvitegravir in HIV-2 is similar to that of HIV-1 [81 ,82] , and virological and immunological response to a HAART regimen containing raltegravir in HIV-2-infected patients experiencing immunovirological failure to several previous ART lines has been reported [83] . Very recently, it has also been reported that HIV-1 and HIV-2 share similar INI resistance pathways. Indeed, both N155H and Q148KR mutations were observed in HIV-2-infected patients failing a raltegravir-containing regimen [84, 85] . It should be noted that HIV-2 is naturally resistant to current NNRTIs and fusion inhibitors [86] ; therefore, the so far, short-term immunological and virological efficacy of an INI-containing regimen also in heavily pretreated HIV-2-infected patients is really promising and clinically relevant.
Promising resistance data have recently been presented on S/GSK1349572, an investigational integrase inhibitor currently in phase II development [87] . Investigators evaluated the phenotypic activity of this agent in vitro against both viruses with site-directed integrase mutations and from clinical isolates, the latter drawn from patients virologically failing raltegravir-containing regimens. Encouragingly, although high-level resistance to raltegravir was common among the 30 clinical isolates with integrase mutations, four displayed a more than fivefold change in susceptibility to S/GSK1349572. These data suggest that S/GSK1349572 may have a role in treating patients who have experienced treatment failure with raltegravir; a study is ongoing to test this hypothesis.
Resistance to CCR5 antagonists
Less is known about resistance to CCCR5 antagonists. Viral entry is an attractive step for the development of new drugs against HIV variants resistant to current antiretroviral drugs and hopefully compounds in this family would also exhibit improved safety profiles relative to currently available antivirals. HIV gains entry into CD4-expressing cells through a series of sequential interactions between the envelope glycoprotein gp120 and the CD4 receptor and one of the two co-receptor molecules, CCR5 or CXCR4, which are expressed on the surface of target cells.
The chemokine receptors CCR5 and CXCR4 are the principal co-receptors for entry of HIV-1 into target cells [88, 89] . Co-receptor selectivity is determined by genetic sequences within gp120, particularly on a highly variable and structurally flexible region termed 'V3' involved in co-receptor binding [90] [91] [92] . Two substances, maraviroc and vicriviroc, specifically designed to inhibit HIV-1 binding to R5 co-receptor are under clinical investigation in antiretroviral-naive or antiretroviral-treated patients. These two drugs exclusively inhibit the replication of R5-tropic HIV variants through an allosteric mechanism after binding to the transmembrane CCR5 co-receptor cavity. There are two ways to escape to CCR5 antagonists: selection of R5X4-tropic or X4-tropic viruses or development of resistance to such compounds.
Maraviroc-resistant viruses generated in vitro appear to be able to use either maraviroc-bound CCR5 or free CCR5 as a co-receptor for cell entry. This mechanism of resistance is characterized phenotypically by doseresponse curves with a reduced maximal percentage inhibition (MPI).
In vivo, different sets of mutations in the V3 loop appear to play a role in resistance to maraviroc in R5 virus [93] . In vitro, the emergence of maraviroc resistance in HIV strain was associated with A21T and I28V mutations in the V3 region of gp120 [94 ] . In vivo, emergence of vicriviroc resistance in an HIV-1 subtype C-infected patient was described, and experiences with chimeric envelopes demonstrated that changes in V3 loop were sufficient to confer vicriviroc resistance [95] . The V3 loop mutations at positions K10R, T12I, F21I, T23R, and G24E confer partial resistance to VCV, with the addition of S11P leading to complete resistance [95] .
Regarding the facts that different set of mutations were described in patients failing a CCR5 antagonist regimen and the extreme genetic variability of the HIV envelope, it is possible to imagine that these mutations, which could be naturally present before introducing the CCR5 antagonists, may lead the virus to become resistant rapidly. In a recent study, it was possible to show that these resistance patterns to maraviroc are present in 7% of maraviroc-naive viruses [96] .
In MOTIVATE trials, amino acid changes within the V3 loop sequence were observed for all resistant R5 viruses, with plateaus in maximal percentage inhibition less than 95%. Site-directed mutagenesis indicated the importance of the mutations in the V3 loop in the maraviroc resistance. The changes in amino acids I20F þ A25D þ I26V were both necessary and sufficient to confer resistance [97] , and this set could be present in viruses in patients naive to CCR5 antagonists. Similar to Lewis et al. [93] , it was described that the V3 changes were concentrated in the stem and tip of the V3 loop and the base of the V3 loop appears to be largely conserved. The two invariant cysteines that form a disulfide bond to create a loop were found in this set of viruses. Mutations concentrated in the stem and tip of the V3 loop appear to play a key role in conferring the maraviroc-resistant phenotype in R5 virus. Changes in the V3 loop may enable the resistant virus to interact with the maraviroc-bound 'disrupted' form of the second extracellular loop (ECL2) of the CCR5 receptor.
There are different mechanisms for virological failure in patients receiving CCR5 antagonists. Although the MOTIVATE or the MERIT study was designed to include only patients with CCR5-tropic virus, patients included in the viral tropism studies changed from CCR5 tropic at screening to dual/mixed at baseline. A rapid outgrowth of pre-existing archived X4 virus is also demonstrated. Furthermore, a resistance to maraviroc in patients failing with R5 virus has been demonstrated. In the future, the lack of maraviroc efficacy on R5 strains could be eventually explained by the presence of amino acid implicated in resistance at baseline. Thus, the V3 loop genotyping could be proposed before introducing CCR5 antagonists.
Further studies are needed to conclude about the magnitude of the genetic barrier of CCR5 antagonists, the kinetic of resistance selection, and the magnitude of cross-resistance between compounds of this class.
Conclusion
The emergence and transmission of HIV-1 isolates resistant to existing antiretroviral drugs has serious clinical consequences. The development of resistance is, therefore, driving research to identify new drugs targeting novel steps in the HIV-1 replication cycle. Recent progress has been made in developing drugs targeting HIV-1 entry and integration. The addition of new drugs to the existing therapeutic arsenal will improve treatment options and clinical prospects particularly for those patients failing current drug regimens based primarily on combinations of RTI and protease inhibitors. Despite the negative impact of drug resistance in the clinic, understanding resistance mechanisms provides a powerful tool to aid the discovery and development of new HIV-1 therapies.
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